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prediction of Molecular Mutations 
in Diffuse Low-Grade Gliomas using 
MR Imaging Features
Zeina A. Shboul  1, James chen  2,3 & Khan M. iftekharuddin  1*
Diffuse low-grade gliomas (LGG) have been reclassified based on molecular mutations, which require 
invasive tumor tissue sampling. Tissue sampling by biopsy may be limited by sampling error, whereas 
non-invasive imaging can evaluate the entirety of a tumor. This study presents a non-invasive analysis 
of low-grade gliomas using imaging features based on the updated classification. We introduce 
molecular (MGMT methylation, IDH mutation, 1p/19q co-deletion, ATRX mutation, and TERT 
mutations) prediction methods of low-grade gliomas with imaging. Imaging features are extracted 
from magnetic resonance imaging data and include texture features, fractal and multi-resolution 
fractal texture features, and volumetric features. Training models include nested leave-one-out cross-
validation to select features, train the model, and estimate model performance. The prediction models 
of MGMT methylation, IDH mutations, 1p/19q co-deletion, ATRX mutation, and TERT mutations 
achieve a test performance AUC of 0.83 ± 0.04, 0.84 ± 0.03, 0.80 ± 0.04, 0.70 ± 0.09, and 0.82 ± 0.04, 
respectively. Furthermore, our analysis shows that the fractal features have a significant effect on the 
predictive performance of MGMT methylation IDH mutations, 1p/19q co-deletion, and ATRX mutations. 
The performance of our prediction methods indicates the potential of correlating computed imaging 
features with LGG molecular mutations types and identifies candidates that may be considered 
potential predictive biomarkers of LGG molecular classification.
Diffuse low-grade gliomas (LGG) are World Health Organization (WHO) Grade II and III gliomas. They are 
infiltrative in their nature and arising from glial cells (astrocytes or oligodendrocytes) of the central nervous 
system (CNS)1,2. Recurrence and malicious progression are possible because of the difficulty in complete tumor 
resection3. A group of these tumors may also develop into glioblastoma (GBM).
An updated classification of diffuse LGG was included in the 2016 WHO Classification of Tumors of the 
CNS4. The new classification of the diffuse LGG depends on the genetic driver mutations (IDH mutations, 1p/19q 
co-deletion, TERT mutations, and ATRX mutations). This new classification correlates well with patients’ treat-
ment and survival, for example, oligodendroglioma, defined by the 1p/19q co-deletion, are associated with longer 
survival compared to astrocytoma, which do not harbor the 1p/19q co-deletion5.
Molecular mutations are determined using invasive methods by obtaining usable tissue samples that have an 
increase in proliferation and neovascularization6. Tissue sampling may also be associated with high cost, morbid-
ity, and even mortality7, and depending on the sample, may undersample tumor components, especially in het-
erogeneous tumors. Consequently, developing alternative methods and non-invasively classify diffuse LGG into 
its different subtypes using imaging features and machine learning techniques have emerged as a promising body 
of research. In this work, we propose a non-invasive imaging-based classification of diffuse LGG using molecular 
mutations and histology prior to invasive tissue sampling.
Isocitrate Dehydrogenase mutations, IDH1, and IDH2 have been found in gliomas8,9, and classifying gliomas 
based on their molecular profiling of IDH status (mutated vs. wild-type) creates clinically distinct groups. IDH 
wild-type gliomas behave aggressively when compared with the IDH mutant gliomas. As a result, patients with 
IDH mutant gliomas tend to have better prognosis10. A 1p/19q co-deletion is considered as a molecular marker 
of oligodendroglioma and is associated with IDH mutation11 and improved survival8. This genetic alteration 
happens when the short arm of chromosome 1 (1p), and the long arm of chromosome 19 (19q) are deleted. 
Another mutation that is strongly associated with 1p/19q co-deletion is the mutations in the promoter region of 
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the telomerase reverse transcriptase (TERT)12. TERT mutation is associated with poor survival in the absence of 
IDH mutation13. ATRX is a somatic mutation in the Alpha-Thalassemia/mental Retardation syndrome known 
as X-linked and may be reported in gliomas including GBM14 and is associated with a significantly better prog-
nosis15,16. In addition, ATRX mutation often occurs with IDH mutations and is almost mutually exclusive with 
1p/19q co-deletion. Another molecular alteration that has a high prevalence of LGG is O6-methylguanine-DNA 
methyltransferase (MGMT) gene promoter methylation17. Patients with a methylated MGMT promoter are asso-
ciated with better overall survival18,19. MGMT promoter has a better impact on overall survival if MGMT meth-
ylation is combined with IDH mutation and 1p/19q co-deletion18.
Diffuse LGG is known for its heterogeneous characteristic that reveals variances in tumor biology. This heter-
ogeneity can be seen through the histological types: astrocytoma, oligoastrocytoma, and oligodendroglioma4,20, 
although oligoastrocytoma is no longer used when molecular markers are available. The heterogeneity can 
be characterized by magnetic resonance imaging (MRI) features21–23, which suggests using MRI features as a 
non-invasive marker in tumor grading and classification24–28.
Our study addresses diffuse LGG grading and classification prediction based on molecular mutations using 
imaging features that are extracted from multimodality raw MRI sequences (T1, contrast-enhanced T1(T1 
Gd), T2 FLAIR, and T2) of the anatomically depicted tumor volume, and texture representations of the tumor 
MRI sequences. The extracted features describe the multi-resolution texture, texture features, volumetric, and 
area-based characteristics. In this study, different molecular (IDH, 1p/19q co-deletion, ATRX, and TERT), and 
MGMT methylation prediction models are introduced. In addition, our study investigates the efficacy of our 
novel texture features the fractal and multi-resolution fractal modeling on the performance of the non-invasive 
prediction of molecular mutation in LGG.
Few studies have shown association between different types of imaging features such as the grey-level 
co-occurrence matrix (GLCM) for texture, volume and area related features, and intensity-based features to the 
tumor classification29–32. While GLCM features may capture the grey-level spatial variation in an image, these 
deterministic features may not be effective in analysis of the random surface structure variation of abnormal 
tumor tissues in MRI. Wavelet features, on the other hand, examine the intensity variation of the tumor tissues 
in different image resolutions33,34. In comparison, the multi-resolution fractal modeling mathematically com-
bines the capabilities of regular texture analysis (e.g., GLCM) and multi-resolution analysis (e.g., wavelets) and, 
hence, may capture the randomly varying complex structure of the tumor tissue texture at different scales. The 
spatial intensity distributions of abnormal brain tissues in MRI have a degree of randomness that are amena-
ble to fractal and multi-resolution fractal texture modeling. Several studies have shown the efficacy of fractal 
and multi-resolution fractal feature analysis for characterization, segmentation and classification of the complex 
abnormal brain tissues in MRI35–38.
Consequently, in this study, we hypothesize that the fractal and multi-resolution fractal modeling may relate 
to the underlying structure of molecular mutations. To the best of our knowledge, this is the first study that 
addresses the potency of fractal and multi-resolution fractal features in molecular mutations prediction.
Material and Methods
Dataset. In this study, we use a total of 108 pre-operative LGG patients described in39–41. Four sequences of 
the MRI are provided with the data set: pre-contrast T1-weighted (T1), post-contrast T1-weighted (T1Gd), 
T2-weighted (T2), and T2 Fluid Attenuated Inversion Recovery (FLAIR). These scans are skull-stripped, re-sam-
pled to 1 mm3 resolution, and co-registered to the T1 template. The dataset provides the segmented sub-regions 
of the LGG: Gadolinium enhancing tumor (ET), the peritumoral edema (ED), and the necrosis along with 
non-enhancing tumor (NCR/NET).
Molecular alterations (IDH mutation, 1p/19q co-deletion, ATRX, and TERT mutation), grade (II and III), and 
clinical data are downloaded from the Genomic Data Commons Data Portal (https://portal.gdc.cancer.gov/). 
Clinical data are de-identified by the Health Insurance Portability and Accountability Act of 1996 (HIPAA). 
The distribution of the data is as follows: (i) IDH mutation: 85 Mutant (of which 27 cases are co-deleted) and 23 
wild-type (WT), (ii) 1p/19q co-deletion: 27 co-deletion and 81 non-co-deletion, (iii) ATRX status: 43 Mutant and 
65 WT, (iv) TERT status: 46 Mutant and 62 WT, and (v) O6-methylguanine-DNA methyltransferase (MGMT) 
promoter methylation: 91 methylated and 14 un-methylated. The range of the patients’ age at the diagnosis is 
20–75 years and the median are 46.5 years.
Methodology. In this study, we introduce different molecular prediction models based on fractal and 
multi-resolution fractal texture features and other MR imaging features. These molecular models include the 
IDH, 1p/19q co-deletion, MGMT, ATRX, and TERT prediction. A classical way to avoid overfitting is to divide 
the dataset into training, validation and testing datasets42. The dataset is randomly partitioned into n pairs (par-
titions) of training (75% of the entire dataset = 81 cases) and testing (25% of the entire dataset = 27 cases). A 
balanced distribution of the target molecular mutation is ensured in the training and testing sets in each molec-
ular prediction model. The features are extracted from multimodality MRI sequences of the tumor volume in 
the training partition. Then, a recursive feature selection is performed to select the number of features and vali-
dated with Leave-One-Out Cross-Validation (LOOCV). The selected features are then trained using an Extreme 
Gradient Boosting (XGBoost) method along with LOOCV. Then, a prediction performance is evaluated using 
the testing partition.
Furthermore, we study the efficacy of fractal and multi-resolution fractal texture features (e.g., 
piecewise-triangular prism surface area (PTPSA), multi-resolution fractional Brownian motion (mBm), and 
Holder Exponent (HE)) extracted from tumor volumes on the performance of the molecular mutation predic-
tion models. Figure 1 shows the overall pipeline of the proposed LGG-XGBoost prediction model for different 
molecular mutations in LGG.
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Feature extraction. In this study, around 680 features are extracted to represent texture, volume, and area of the 
tumor and its sub-regions (edema, enhancing tumor, and necrosis). These features include 41 texture features43 
extracted from the tumor volume in raw MRI (T1Gd, T2, and FLAIR) sequences and an additional three different 
texture characterizations of the tumor region. The three texture characterizations are as follows:
•	 fractal characterization using our PTPSA44 modeling,
•	 multi-resolution mBm36 modeling,
•	 and the characterization Holder Exponent (HE)45 modeling of the tumor region.
The computational algorithm of the PTPSA, mBm, and the HE is found in36,44,46. Furthermore, six 
histogram-based statistics (mean, variance, skewness, kurtosis, energy, and entropy) features are also extracted 
from the different tumor sub-regions (edema, enhancing tumor, and necrosis), respectively.
In addition, we extracted 12 volumetric features: the volume of the whole tumor, the volume of the whole 
tumor with respect to the brain, the volume of sub-regions (edema, enhancing tumor, and necrosis) divided by 
the whole tumor, the volume of sub-regions (edema, enhancing tumor, and necrosis) divided by the brain, the 
volumes of the enhancing tumor and necrosis divided by the edema, the summation of the volume of the edema 
and enhancing tumor, the volume of the edema divided by the summation of the volume of enhancing tumor and 
necrosis, and the volume of the necrosis divided by the summation of the volume of the edema and enhancing 
tumor. Finally, nine-volume properties (area, bounding box, centroid, perimeter, major axis length, minor axis 
length, eccentricity, orientation, solidity, and extent) are extracted from the tumor volume and from three view-
points (x, y, and z-axes) of the tumor and its sub-regions (edema, enhancing tumor, and necrosis).
Texture features are analyzed using MATLAB-based software developed by Vallières et al.43. Fractal character-
ization, multi-resolution fractal characterization, HE characterization, and volumetric features are analyzed using 
MATLAB-based in-house software.
Molecular mutation prediction model and feature selection. The molecular mutation prediction model is per-
formed on the training set using nested LOOCV to avoid an optimistic performance estimate. Recursive feature 
selection is performed in the inner loop to find optimum features set. In each mutation prediction analysis, fea-
ture selection using RFS is done using the training set that is (75%) of the whole 108 cases. Because we repeat the 
prediction analysis of training and testing n times, eventually each case of the 108 cases would have appeared in 
the training sets. The LOO cross-validated performance of the molecular mutation prediction model is estimated 
in the outer loop. The molecular mutation prediction model is performed using the R statistical packages Caret 
and XGBoost (www.r-project.org).
Recursive feature selection (RFS) is implemented by first fitting a Random Forest (RF) model to all features. 
Each feature is ranked by its importance, and the least important features are removed from the current feature 
set. Then, this step is repeated recursively until the optimum features set that has the best performance is reached. 
In our implementation of recursive feature selection, the number of features in the features’ sets are 2, 3, 5, 7, 9, 11, 
13, and 15 features. In addition, the best performance is determined by maximizing the area under the receiver 
operating characteristic (ROC) metric. The features’ set that provides the combination of features that maximize 
the area under the ROC (AUC) is chosen for training in the prediction model. Using recursive feature selection, 
the maximum number of selected features is fifteen, so that the training samples (eighty-one cases) are at least 5 
times the number of features to reduce model overfitting.
In our study, XGBoost is utilized as a classification and prediction model using the optimum features set as 
input and molecular mutation information as the target output. XGBoost47 is an advanced tree boosting 
Figure 1. The general outline of the LGG-XGBoost molecular prediction model. Note that this analysis is 
repeated n times (randomly chosen) to generate a more reliable performance.
I . Segmented Tmnor 
Data 
fo<~M@l 2. Extract Selected Features 
,-l!-------, CLM •2 
'""" ~ 
••• •• • 
4Scientific RepoRtS |         (2020) 10:3711  | https://doi.org/10.1038/s41598-020-60550-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
supervised machine learning technique that is effective in handling imbalanced datasets. XGBoost is widely used 
in classification and regression tasks. For a given dataset D  with s  samples and m  features 
= = ∈ ∈ D x y D s x y{( , )}( , , )i i i
m









where xi is the feature/input vector, yi is the target/output variable, and f x( ) is a function in the functional space 
F, and F is a set of all possible classification and regression trees. One of the major advantages of using XGBoost 
is that XGBoost provides L1 and L2 regularization. L1 regularization handles sparsity, whereas L2 regularization 
reduces overfitting. In addition, we choose XGBoost because it is known for handling an imbalanced dataset. A 
detailed mathematical derivation of the XGBoost algorithm is found in Chen et al.47.
The final molecular mutation prediction model (that is used for the testing set) is obtained by fitting the opti-
mum features’ set that maximize the performance in the inner loop (over all the outer cross-validation loops). 
Note, if there are more than one feature sets maximizes the inner loop performance, then the common feature 
between the features’ sets are used. The prediction performance of the final molecular mutation model is tested 
using the paired testing sets (partitions).
Finally, in order to study the efficacy of fractal and multi-resolution fractal texture features used in this study 
(e.g., PTPSA, mBm, and Holder Exponent) on the performance of the proposed prediction models as shown in 
Fig. 1, we perform molecular prediction analyses with and without these texture features, respectively. The whole 
process in Fig. 1 is repeated n times independently with n different training/testing set pairs. The n number of 
repetitions is a random number between 10 and 15 that are generated for each model.
Evaluation. The molecular models are validated using separate testing sets and the prediction performance 
(test performance) of the trained XGBoost model is estimated using AUC, sensitivity, and specificity. After n 
times of independent repetitions, ANOVA test is used to compare the difference in the prediction performance 
between two models with and without the fractal and multi-resolution fractal texture in the prediction models. 
In addition, ANOVA is used to analyze the significant association between features and the different molecular 
mutations. The survival groups that are formed using the significant features are compared using Kaplan-Meier 
curves and the log-rank test. The hazard ratio of features is determined using the Cox proportional hazards 
model and assessed using the likelihood-ratio test. Finally, the evaluation step for Survival is conducted using R 
statistical packages.
Results
Around 680 imaging features are extracted from multimodality MRI sequences. Recursive feature selection is 
used to find the optimum number of significant features for each molecular mutation prediction model. Our anal-
ysis of the different prediction models are repeated independently n times with different training and testing pairs 
(partitions). Table 1 displays the number of repetitions n, LOOCV performance, and the test performance of the 
different prediction models when including/removing texture characterization of the fractal and multi-resolution 
fractal of PTPSA, mBm, and Holder Exponent characterization.
MGMT methylation model. The most frequent features that are selected are the necrosis width in the 
Z planar, the histogram entropy of the mBm characterization on the whole tumor, and size ratio between the 
enhancing tumor and the necrosis. The necrosis width in the Z planar and the histogram entropy of the mBm 
characterization on the whole tumor features are significantly (ANOVA test, p-value < 0.05) associated with 
methylated MGMT, whereas the size ratio between enhancing tumor and necrosis is associated significantly with 
un-methylated MGMT as shown in Fig. 2A.
Cross-Validated 
performance n repetition
With fractal & multi-resolution fractal features Without fractal & multi-resolution fractal features
AUC. Sens. Spec. AUC. Sens. Spec.
MGMT Methylation 11 0.86 ± 0.03 0.88 ± 0.02 0.80 ± 0.09 0.87 ± 0.04 0.90 ± 0.02 0.66 ± 0.10
IDH mutation 13 0.85 ± 0.04 0.90 ± 0.03 0.75 ± 0.05 0.79 ± 0.07 0.89 ± 0.08 0.75 ± 0.07
1p/19q co-deletion 15 0.83 ± 0.03 0.78 ± 0.08 0.83 ± 0.03 0.80 ± 0.05 0.63 ± 0.08 0.87 ± 0.02
ATRX mutation 10 0.77 ± 0.06 0.62 ± 0.09 0.80 ± 0.03 0.80 ± 0.04 0.77 ± 0.06 0.76 ± 0.03
TERT 14 0.82 ± 0.04 0.70 ± 0.06 0.83 ± 0.04 0.82 ± 0.04 0.82 ± 0.04 0.76 ± 0.05
Prediction/test Performance
MGMT Methylation 11 0.83 ± 0.04 0.93 ± 0.05 0.73 ± 0.13 0.70 ± 0.12 0.90 ± 0.07 0.50 ± 0.24
IDH mutation 13 0.84 ± 0.03 0.90 ± 0.06 0.79 ± 0.09 0.75 ± 0.07 0.83 ± 0.11 0.66 ± 0.18
1p/19q co-deletion 15 0.80 ± 0.04 0.75 ± 0.08 0.85 ± 0.06 0.75 ± 0.07 0.67 ± 0.12 0.84 ± 0.10
ATRX mutation 10 0.70 ± 0.09 0.69 ± 0.06 0.83 ± 0.10 0.66 ± 0.10 0.65 ± 0.16 0.68 ± 0.18
TERT 14 0.82 ± 0.04 0.77 ± 0.12 0.86 ± 0.09 0.78 ± 0.07 0.77 ± 0.11 0.79 ± 0.11
Table 1. LOO cross-validated performance of the outer-loop, and the predictive/test performance of the different 
LGG molecular prediction models.
I I 
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The LOOCV performance and the prediction performance on the testing set for predicting the MGMT 
methylation status using imaging features are illustrated in Table 1 and Fig. 2B. The prediction performance 
using the test partitions achieves an AUC, a sensitivity, and a specificity of 0. 0.83 ± 0.04, 0.93 ± 0.05, and 
0.73 ± 0.13, respectively. Removal of our fractal and multi-resolution fractal features from MGMT meth-
ylation prediction model have an effect on the prediction performance on the testing set. AUC and speci-
ficity drop significantly (ANOVA test, p-value = 0.003, and 0.01, respectively) when the fractal features are 
removed (Fig. 2B).
IDH mutation model. Our analysis reveals that the tumor correlation, the vertical orientation of edema 
major axis (the angle between the edema major axis and the vertical axis), size ratio between the enhancing tumor 
and the necrosis, and the complexity of holder exponent of the tumor are among the most frequently selected 
features to predict IDH-mutated status in LGG. Higher values of the complexity of the holder exponent of the 
tumor, the size ratio between the enhancing tumor and the necrosis, and higher values of the vertical orientation 
of edema major axis associate significantly (ANOVA test, p-value < 0.005) with WT IDH status. Whereas the 
tumor correlation associates significantly (ANOVA test, p-value < 0.005) with mutated IDH status as illustrated 
in Fig. 3A. Figure 3B shows the clustering of IDH status using the most frequent features in Fig. 3A. The clustering 
between the mutated IDH and WT IDH is demonstrated using t-Distributed Stochastic Neighbor Embedding48 
(tSNE).
In addition, the tumor correlation, the vertical orientation of edema major axis, and the complexity of holder 
exponent of the tumor features carry a hazard ratio [HR] of 0.562 (95% CI, 0.381–0.828), 2.655 (95% CI, 1.617–4.36), 
and 1.553 (95% CI, 1.165–2.07) with a likelihood ratio test p-value = 0.005, 0.0001, 0.008, respectively. Because 
these features are continuous features, the HRs interpolate as follows: the risk of death increases (or decreases 
if HR < 1) by (HR-1) × 100% for every 1-standard deviation increase in that feature. The LOOCV and the 
test performance of the proposed IDH models are illustrated in Table 1. The prediction performance using the 
testing partitions achieves an AUC, sensitivity, and specificity of 0.84 ± 0.03, 0.90 ± 0.06, and 0.79 ± 0.09, respec-
tively. Note that the AUC and specificity of the IDH status prediction model drop significantly to 0.75 ± 0.07 and 
0.66 ± 0.18 (ANOVA test, p = 0.0001 and p = 0.028, respectively) after removing features extracted from fractal 
and the multi-resolution modeling (Fig. 3C).
1p/19q co-deletion model. The necrosis upper-left bounding box location, the histogram entropy of mBm 
characterization of the whole tumor, and the horizontal coordinate of necrosis centroid are the most frequent 
optimum features that are selected in our proposed 1p/19q codeletion models. These three features show sig-
nificance (ANOVA test, p-value < 0.0001) associated with the existence of the 1p/19q co-deletion. Our analy-
sis shows frontal tumors are associated significantly (ANOVA test, p-value < 0.0001) with 1p/19q co-deletion 
mutations (Fig. 4A). The performance of the proposed co-deletion prediction LOOCV model is illustrated in 
Table 1. The 1p/19q co-deletion performance using the test partitions achieve an AUC of 0.80 ± 0.04, a sensi-
tivity of 0.75 ± 0.08, and a specificity of 0.85 ± 0.06. In addition, the efficacy of our fractal and multi-resolution 
fractal texture features on the performance of the co-deletion prediction model is significant as shown in (Fig. 4B 
and Table 1). The AUC and the sensitivity of the co-deletion prediction model drop significantly (ANOVA test, 
p-value of 0.024 and 0.029, respectively) after removing features extracted from our fractal and multi-resolution 
fractal features in the 1p/19q co-deletion prediction model to 0.75 ± 0.07 and 0.67 ± 0.12 (without fractal fea-
tures). Figure 4C illustrates the location of the centroid and the upper-left bounding box of the necrosis. The 
histogram entropy of mBm of the tumor volume offers HR of 0.59 per standard deviation (95% CI, 0.35–0.97) 
with a likelihood ratio test p-value of 0.037.
Figure 2. MGMT methylation models. (A) Distribution of the most selected features in discriminating MGMT 
mutated and WT, and (B) MGMT prediction model performance using the train and test partitions with and 
without fractal texture features. Error bars represent two standard deviations. The asterisk *illustrates the 
significant difference between the two measurements.
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ATRX Mutation Model. The information content of correlation and the histogram mean of the tumor vol-
ume of the most frequently selected features are employed in the XGBoost model to train and predict ATRX status. 
The distribution of the most frequent features is illustrated in Fig. 5A. Higher values of information of correlation 
are associated significantly (ANOVA test, p-value < 0.001) with ATRX wild-type. Whereas Higher values of histo-
gram mean are associated significantly (ANOVA test, p-value < 0.001) with mutated ATRX. The ATRX prediction 
model achieves prediction performance of an AUC of 0.70 ± 0.09, a sensitivity of 0.70 ± 0.06, and a specificity of 
0.83 ± 0.10 using the test partitions. Removing features extracted from our fractal and multi-resolution fractal 
modeling from the ATRX prediction model has a significance specificity drop to 0.68 ± 0.18 performance of the 
model with p-value = 0.03 (ANOVA test) as shown in Fig. 5B.
TERT mutation model. A review of the most frequently selected imaging features of TERT mutation pre-
diction model, we notice that the information content of correlation of the tumor volume, the edema upper-left 
bounding box location, and the inverse difference moment of HE characterization of tumor volume are the most 
frequently selected features (Fig. 5C). The inverse difference moment of HE characterization of tumor volume 
offers HR of 0.612 per standard deviation (95% CI, 0.405–0.924) with a likelihood ratio test p-value = 0.027. The 
TERT prediction models’ performances are illustrated in Table 1. The TERT prediction performance using the 
test partitions achieves an AUC of 0.82 ± 0.04, a sensitivity of 0.77 ± 0.12, and a specificity of 0.86 ± 0.09, respec-
tively. Removing our fractal and multi-resolution fractal texture modeling has no significant effect on the TERT 
performance of prediction models when using the test partitions as shown in Table 1.
IDH/co-deletion model. Molecular classification based on the status of IDH mutations and 1p/19q 
co-deletion results in distinguishing three LGG molecular subtypes that have a distinct clinical behavior: IDH 
WT, IDH mutant with 1p/19q co-deleted, and IDH mutant with 1p/19q non-co-deleted. In this work, we combine 
these two mutations and perform a 3-class prediction (i.e., IDH/co-deletion prediction model) using the method-
ology illustrated previously and shown in Fig. 1.
The IDH mutation model and the 1p/19q co-deletion model show their superior performance when using 
fractal and multi-resolution fractal modeling features along with other non-fractal (i.e., texture and volumet-
ric) features. Consequently, we develop 3-class IDH/co-deletion models utilizing fractal and other non-fractal 
features. The whole process of training and testing is repeated 5 times. The distribution of the three molecular 
Figure 4. 1p/19q codeletion models. (A) Distribution of the most selected features in discriminating 1p/19q 
codeletion and non-codeletion, (B) Performance comparison of codeletion classifier models using the train 
and test partitions with and without fractal features. (C) Example of FLAIR images illustrates the location of the 
necrosis centroid and the upper-left location of the necrosis bounding-box. Error bars represent two standard 
deviations. The asterisk *illustrates the significant difference between two measurements.
Figure 3. IDH models. (A) Distribution of the most selected features in discriminating among IDH mutated 
and WT cases in LGG, (B) 2-D t-Distributed Stochastic Neighbor Embedding (t-SNE) visualization using only 
the 4 features in (A,C) Performance comparison of IDH prediction model using the train and test partitions 
with and without fractal features. Error bars represent two standard deviations. The asterisk *illustrates the 
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subtypes is as follows: 23 cases represent IDH WT, 27 cases represent IDH mutant with 1p/19q co-deleted, and 58 
cases represent IDH mutant with 1p/19q non-co-deleted.
Our analysis using the Chi-square test confirms a significant association (p-value = 0.004) between IDH status 
and 1p/19q codeletion. Additionally, our analysis shows that IDH WT patients carry HR of 3.1 (likelihood ratio 
test p-value = 0.007) and have significantly shorter survival when compared to IDH mutated patients (19.9 vs. 
65.7 months, log-rank test p-value = 0.004). The association between IDH status and overall survival remains 
significant after stratifying for 1p/19q codeletion (likelihood ratio test p-value = 0.005).
Table 2 shows the performance of the 3-class training and testing of the IDH/co-deletion model where the 
sensitivity and the specificity are reported per class, multiclass AUC is calculated as described in49, and the overall 
accuracy is calculated based on the number of correctly classified in all classes to the total number of cases.
Note this simultaneous prediction of multiple genes may be more clinically valuable when compared to con-
ventional single gene prediction models.
Discussion
The 2016 WHO classification of diffuse LGGs heavily weighs molecular mutations classifying primary brain tum-
ors with particular importance assigned to IDH mutation, 1p/19q co-deletion, ATRX mutation, TERT mutations, 
and MGMT methylation. Our study on diffuse LGG is largely able to predict the presence of these important 
molecular mutations based on MR imaging features. Therefore, prediction of tumor aggressiveness (based on 
molecular mutations) may be achieved through non-invasive imaging features as an adjunct to traditional visual 
morphologic diagnosis and invasive tissue sampling.
In this work, the number of originally extracted imaging features (six hundred eighty features) is higher than 
the number of samples (eighty-one cases) in the training dataset, which may cause overfitting. To address possible 
Figure 5. Distribution of the most selected feature in discriminating (A) mutated ATRX and WT, (B) 
Performance comparison of ATRX classifier models using the train and test partitions with and without fractal 
features. Error bars represent two standard deviations. The asterisk *illustrates the significant difference 
between the two measurements, and (C) mutated TERT and WT.
Cross-Validated performance Overall Accuracy Sens. Spec. Multiclass AUC
IDH WT
0.80 ± 0.01
0.73 ± 0.01 0.93 ± 0.004
0.75 ± 0.06IDH mutation and 1p/19q co-deletion 0.71 ± 0.02 0.90 ± 0.03




0.73 ± 0.09 0.92 ± 0.03
0.80 ± 0.04IDH mutation and 1p/19q co-deletion 0.71 ± 0.00 0.89 ± 0.05
IDH mutation and 1p/19q non-co-deletion 0.84 ± 0.09 0.85 ± 0.08
Table 2. LOO cross-validated performance of the outer-loop, and the predictive/test performance of the IDH/
co-deletion model using fractal and multi-resolution fractal features and other non-fractal features.
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overfitting, we implement feature selection in the training model that offers a maximum of fifteen selected fea-
tures. Figure 6 illustrates the effect of the number of features on the cross-validated performance of the different 
mutation prediction models. The average AUC performances and the standard error of the different prediction 
models improve when the number of features is greater than 9. Note that the standard error mostly plateaus when 
the number of features varies between 9–15 (standard error reflects instability).
For the fractal and multi-resolution fractal texture model in Table 1, the AUC predictive performance of 
MGMT, 1p/19q co-deletion, and ATRX models drop to 0.83 ± 0.04, 0.80 ± 0.04, and 0.70 ± 0.09, respectively. This 
statistically non-significant drop in performance (ANOVA test, p = 0.076, p = 0.073, and p = 0.071 respectively) 
when compared to their AUC cross-validated performance, may suggest minimal overfitting for these models. 
The AUC predictive performances of IDH and TERT models are almost comparable to their cross-validated per-
formance as shown in Table 1 that suggests there is no overfitting in these two models.
For the non-fractal models in Table 1, the AUC predictive performance of IDH, 1p/19q co-deletion, and 
TERT models drop to 0.75 ± 0.07, 0.75 ± 0.07, and 0.78 ± 0.07 respectively. This statistically non-significant drop 
(ANOVA test, p = 0.182, p = 0.056, and p = 0.062 respectively) when compared to their AUC cross-validated 
performance, may suggest minimal overfitting for these models. However, the poor predictive performances of 
the non-fractal MGMT and non-fractal ATRX models when compared with their non-fractal cross-validated 
performances are a sign of overfitting.
Note “optimally chosen” features in the non-fractal models (in Figs. 2–4) are not selected by simply replacing 
the fractal features by alternate features (or by using the same number of predictors as in the fractal models). In 
each mutation model (fractal or non-fractal), RFS (and thus selecting “optimally chosen” features) is performed 
independently. In our implementation of RFS for fractal or non-fractal models in Figs. 2–4, the possible number 
of features in the features’ sets may be 2, 3, 5, 7, 9, 11, 13, and 15, respectively. The maximum number of selected 
features is set to 15 such that the training samples (81 cases) are at least 5 times the number of features to reduce 
the possibility of model overfitting.
Finally, we compare the performances of our prediction models with a list of state-of-the-art studies as illus-
trated in Table 3. However, a direct comparison between the performances of our proposed models and these 
studies may not be relevant because of the different datasets.
Our study on MGMT methylation prediction shows that MGMT methylation correlates with high values of 
fractal texture features such as histogram entropy of mBm for tumor volume. Entropy measures randomness 
or uncertainty in the tumor. The analysis reveals that high histogram entropy of mBm associates with the less 
aggressive methylated MGMT status and carries HR of 0.579 per standard deviation (95%CI, 0.345, 0.969) with 
a likelihood ratio test p-value = 0.035. The study further shows that the size ratio between enhancing tumor and 
necrosis correlates significantly with un-methylated MGMT, which indicates that the high aggressive MGMT 
un-methylated LGG, the higher the values of the size ratio. The MGMT methylation prediction study by Kanas 
Figure 6. The effect of number of features on cross-validated performance of the different mutation models. 
(A) MGMT prediction model, (B) prediction model, (C) 1p/19q co-deletion prediction model, (D) ATRX 
prediction model, and (E) TERT prediction model. The y axis represents mean AUC of every feature set which 
is computed from all independent n repetitions, and error bars represent two standard deviations. The x axis 
represents the number of selected features.
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et al.50 for patients with GBM reports the size of the tumor with respect to necrosis as one of the significant fea-
tures. Our analysis shows that removing the texture features such as fractal and the multi-resolution fractal (of 
PTPSA, mBm, and Holder Exponent) characterization is significant on the AUC and specificity performance of 
the MGMT methylation model. The GBM study conducted by Kanas et al.50 (Table 3) proposes an MGMT predic-
tion model using volumetric, morphological, and locational MR imaging features, respectively. In our study, we 
use texture features and volumetric features. Moreover, the whole process of the prediction model in our current 
study including feature extraction is automated, unlike the proposed work by Kanas et al.50. Another study by 
Han et al.51 (Table 3), the authors use a bi-directional convolutional recurrent neural network to predict MGMT 
methylation status. A major difference between our MGMT prediction model and the method proposed by Han 
et al.51 is that our model mainly utilizes quantitative imaging features that can be correlated with tumor biology.
In addition, our IDH mutation prediction model indicates that the tumor correlation associates significantly 
with mutated IDH and offers HR of 0.562 per standard deviation with a likelihood ratio test p-value = 0.005. In 
addition, our analysis shows that the complexity of HE of enhancing tumor associates significantly with WT IDH 
status with HR of 1.553 per standard deviation with a likelihood ratio test p-value = 0.008. Complexity is related 
to the visual information content and the shape of the object. Texture with higher information content and with 
a large number of edges are considered complex52. This outcome is in agreement with another gliomas study by 
Wang et al.53 which reports that the enhancement patterns predict the prognosis in IDH1 mutations in Anaplastic 
gliomas. Our analysis also shows that the size ratio between enhancing tumor and necrosis is a significant predic-
tor feature of the IDH status. This feature is also a significant predictor of MGMT status, which can be explained 
by the fact that MGMT methylation is associated with IDH status as reported by Mukasa et al.54. In the IDH 
prediction model by Yu et al.55 (Table 3), the authors use 110 imaging features and SVM to classify IDH status 
with Grade II glioma patients. Even though the dataset we use in the IDH mutation prediction is not the same as 
the dataset is used by Yu et al.55, the dataset used in our study is more diverse with data from both Grade II and 
III, and this reflects higher reliability of the performance of the IDH status prediction model. A different study 
by Ding et al.56 (Table 3) on 76 LGG patients utilizes MR imaging features along with MR spectroscopic data 
to predict IDH mutations using a binary logistic regression model. The authors achieved the best performance 
when utilizing MR spectroscopic data. When comparing the performance of our IDH prediction and the best 
performance of Ding et al.56, our model achieves better AUC, sensitivity, and specificity as illustrated in Table 3.
Furthermore, our study on the 1p/19q co-deletion prediction model indicates that the location of the 
upper-left necrosis bounding box and horizontal coordinate of the necrosis centroid (illustrated in Fig. 4C) are 
among the most predictive features. This outcome is in agreement with different studies57–59 which report that 
gliomas with 1p/19q co-deletion are associated with the tumor location. In addition, our analysis shows that 
higher values of histogram entropy of mBm texture of tumor volume are associated significantly with the exist-
ence of 1p/19q co-deletion. Moreover, our analysis reveals that removing the texture representation of fractal 
and multi-resolution fractal from the 1p/19q co-deletion prediction model decreases the AUC and specificity 
Our Proposed Prediction Models
108 LGG (75% training, 25 testing) Other Models
Models
Test Performance (using testing sets)
n Study (dataset) PerformanceAUC Sens. Spec.
MGMT 0.83 ± 0.04 0.93 ± 0.05 0.73 ± 0.13 11
Kanas et al.50 (86 GBM patients)
Accuracy Sens. Spec.
0.736 0.85 0.66
Han et al.51 (159 LGG; 70% training, 
15% validation, and 15% testing)
Dataset AUC Accuracy Precision Recall
Test 0.61 0.62 0.67 0.67
Validation 0.66 0.67 0.67 0.73
IDH 0.84 ± 0.03 0.90 ± 0.06 0.79 ± 0.09 13
Yu et al.55 (110 training, 30 independent 
validation)
Dataset AUC Accuracy Sens. Spec.
Training 0.86 0.80 0.83 0.74
Validation 0.79 0.83 0.88 0.67
Ding et al.56 (67 LGG: 48 IDH Mutant, 
28 IDH WT)
AUC Accuracy Sens. Spec. PPV NPV
0.758 0.793 0.8947 0.60 0.8095 0.75
1p/19q co-
deletion 0.80 ± 0.04 0.75 ± 0.08 0.85 ± 0.06 15
Akkus et al.60 (159 LGG (252 slices), 
validation (68 slices), and testing 
(90 slices)).
Dataset Accuracy Sens. Spec.
Testing 0.877 0.933 0.822
Van der Voort et al.61 Training: 284 LGG
Testing: 129 LGG
Dataset: Accuracy AUC Sens. Spec. F1 score Precision
Training 0.698 0.755 0.657 0.721 0.701 0.570
Testing 0.693 0.723 0.732 0.617 0.697 0.787
ATRX 0.70 ± 0.09 0.69 ± 0.06 0.83 ± 0.10 10 Li et al.
62 (95 LGG, 63 training, 32 
validation, and 91 external validation
Dataset Accuracy AUC Sens. Spec.
Validation 0.938 0.925 0.833 1.00
External 0.769 0.725 0.571 0.857
TERT 0.82 ± 0.04 0.77 ± 0.12 0.86 ± 0.09 14 Wang et al.
63 (39 LGG: 30 TERT WT, 
and 8 TERT Mutant) LOOCV AUC (95% CI) of 0.874 (0.756–0.992)
Table 3. Comparison between our proposed molecular mutations models and state-of-the art glioma grading 
models.
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significantly. The test prediction performance of the 1p/19q co-deletion prediction model drops (after removing 
the fractal features). A study by Akkus et al.60 (Table 3) with LGG patients (where each patient has 3 MRI slices) 
proposes 1p/19q co-deletion prediction using a convolutional neural network (CNN). Their method achieves bet-
ter sensitivity; however, our method achieves slightly better specificity. In addition, Akkus et al.60 do not consider 
the global information of the tumor, since their dataset uses only 3 slices of the MRI sequence of each patient as 
input, not the whole volume of the tumor. Another recent study by van der Voort et al.61 (Table 3) utilizes MR 
imaging features along with patients’ age and sex using an SVM classifier to predict 1p/19q co-deletion in LGG 
patients. The authors use 284 LGG patients for training and another 129 LGG patients for testing. Their analysis 
reveals that the cranial/caudal location of the tumor is one of the most important features in predicting 1p/19q 
co-deletion. Comparing the performance of our 1p/19q co-deletion prediction and the performance of van der 
Voort et al.61, our 1p/19q co-deletion prediction model outperforms their model as illustrated in Table 3.
Our analysis of ATRX-status prediction shows that tumor information measure of correlation imaging feature 
and histogram mean tumor volume are the most frequently selected features. Higher values of information meas-
ure of correlation are associated significantly with WT ATRX status. This is in agreement with an ATRX mutation 
prediction study by Li et al.62 (Table 3) in patients with low-grade glioma, where the authors use MRI texture 
feature and LASSO regression model. In their model, the information measure of correlation is one of the features 
that is used to predict ATRX mutation. In addition, our analysis shows that the tumor information measure of 
correlation is one of the most frequent features in the TERT model as well. This can be explained by the fact that 
ATRX and TERT mutations are mutually exclusive.
The TERT prediction analysis shows that tumor information-measure of correlation and upper-left edema 
bounding box are the most frequently selected features. Higher values of these two features are significantly asso-
ciated with mutated TERT status. The information-measure of correlation assesses the correlation/dependency 
between two gray-levels using mutual information content. High values of Information measure of correlation 
are associated with mutated TERT. In addition, our analysis suggests that the higher values of Inverse difference 
moment of HE associates significantly with WT TERT and offers HR = 0.612 per standard deviation with a like-
lihood ratio test, p-value = 0.03. Inverse difference moment measures local homogeneity. High values of inverse 
difference moment of HE tumor predict the less aggressive WT TERT. Recently, Wang et al.63 (Table 3) explore 
survival prediction and TERT mutations in 39 LGG (30 WT, and 9 Mutant) patients and achieve a LOOCV AUC 
of 0.874 (95% CI: 0.756–0.992). The authors propose a TERT prediction model using 24 imaging features selected 
using Principle Component Analysis (PCA) and classified using the Partial Least Squares (PLS). While their 
method achieves a slightly higher AUC, the sensitivity, specificity, or the confusion matrix are not provided for 
such an imbalanced dataset.
Overall, our analysis shows that the necrosis location and the necrosis volume-related features are very 
important (most frequently selected features) in MGMT, IDH, and 1p/19q co-deletion prediction. Edema 
volume-related features are very important in IDH and TERT prediction models. Fractal features have a signifi-
cant effect on MGMT, IDH, 1p/19q co-deletion, and ATRX prediction models. Further analysis on the most fre-
quent features in each prediction model, we notice that the effect of thresholding the value of standardized feature 
around the median can stratify the 108 cases significantly (log-rank test, p-value < 0.05) into two survival groups 
(Fig. 7A–C). The features and the median survival of each group are:
•	 the size ratio between the enhancing tumor and necrosis stratifies the 108 cases into two groups with a median 
survival of 87.4 months vs 30.7 months,
•	 the correlation of the tumor volume stratifies the 108 cases into two groups with a median survival of 114 
months vs 46 months,
•	 and the vertical orientation of edema major axis stratifies the 108 cases into two groups with a median sur-
vival of 114 vs 44 months.
In summary, this study presents molecular prediction model designs from traditional MRI data based on the 
2016 update of the WHO classification of LGG of the CNS. Our prediction model performance shows promise 
when compared to different methods and models in the literature. An association among computed MR imaging 
features and the molecular mutations LGG was established. The methods discussed in our study are important 
Figure 7. The effect of thresholding (A) the size ratio between the enhancing tumor and necrosis, (B) tumor 
correlation, and (C) vertical orientation of edema major axis around the median. P-values are computed using 
the likelihood ratio test.
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steps towards non-invasive imaging classification of diffuse LGG based on molecular mutations prior to invasive 
tissue sampling. In this work for the first time in literature, we hypothesize that fractal and multi-resolution frac-
tal features have an association with molecular prediction. The feature selection using RFS and the subsequent 
prediction results in Table 1 confirm our hypothesis by showing the efficacy of these fractal features in glioma 
prediction. Therefore, this work may be considered as a validation of previously hypothesized fractal biomarkers, 
and, hence, may have potential for generalizability for other types of tumors.
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